| 11306111 |
Organophosphate derivatives |
Raj K. Raheja |
2022-04-19 |
| 11306399 |
Nanoparticle compositions |
Raj K. Raheja, Jason A. KAHANA |
2022-04-19 |
| 11123317 |
Compositions for the treatment of autodigestion |
Thomas Hallam, John Rodenrys |
2021-09-21 |
| 10793894 |
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2020-10-06 |
| 10677786 |
Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2020-06-09 |
| 10260084 |
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2019-04-16 |
| 9915649 |
Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2018-03-13 |
| 9775821 |
Compositions for the treatment of autodigestion |
Thomas Hallam, John Rodenrys |
2017-10-03 |
| 9677116 |
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2017-06-13 |
| 9340822 |
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2016-05-17 |
| 9314442 |
Compositions for the treatment of autodigestion |
Thomas Hallam, John Rodenrys |
2016-04-19 |
| 9222120 |
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition |
Brett E. Crawford, Jilllian R. Brown, Charles A. Glass, Jim R. Beitel |
2015-12-29 |
| 8809009 |
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2014-08-19 |
| 8771974 |
Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2014-07-08 |
| 8232073 |
Quantification of non-reducing end glycan residual compounds |
Brett E. Crawford, Jillian R. Brown, Charles A. Glass, Jim R. Beitel |
2012-07-31 |